Table 3.
Breast cancer genes differentially expressed between CAW and AAW patient populations
| Gene | Description | CAWa | AAWb | CAW/AAWc | P-valued |
|---|---|---|---|---|---|
|
Genes Associated with Breast Cancer Prognosis | |||||
| AR |
Androgen receptor |
0.99 |
0.38 |
2.60 |
0.002 |
| BCL2 |
B-cell CLL/lymphoma 2 |
0.65 |
0.20 |
3.28 |
0.010 |
| CCND1 |
Cyclin D1 |
0.78 |
0.28 |
2.75 |
0.030 |
| CDKN1A |
Cyclin-dependent kinase inhibitor 1A |
2.07 |
0.90 |
2.29 |
0.002 |
| CDKN1B |
Cyclin-dependent kinase inhibitor 1B |
1.68 |
0.74 |
2.26 |
0.001 |
| CDKN2A |
Cyclin-dependent kinase inhibitor 2A |
1.35 |
3.55 |
0.38 |
0.046 |
| ERBB2 |
V-erb-b2 erythroblastic leukemia viral oncogene homolog 2 |
1.61 |
0.63 |
2.56 |
0.012 |
| ESR1 |
Estrogen receptor 1 |
1.79 |
0.46 |
3.91 |
0.023 |
| GATA3 |
GATA binding protein 3 |
1.57 |
0.17 |
9.33 |
0.001 |
| IGFBP2 |
Insulin-like growth factor binding protein 2, 36 kDa |
1.53 |
0.73 |
2.11 |
0.005 |
| IL6ST |
Interleukin 6 signal transducer |
1.15 |
0.44 |
2.64 |
0.005 |
| KRT19 |
Keratin 19 |
1.44 |
0.71 |
2.03 |
0.012 |
| MUC1 |
Mucin 1, cell surface associated |
1.77 |
0.36 |
4.94 |
0.004 |
| PGR |
Progesterone receptor |
0.77 |
0.33 |
2.34 |
0.012 |
| SERPINE1 |
Serpin peptidase inhibitor, clade E, member 1 |
7.59 |
3.18 |
2.38 |
0.014 |
|
Genes Associated with Response to Chemotherapy | |||||
| HSPB1 |
Heat shock 27 kDa protein 1 |
0.98 |
0.46 |
2.14 |
0.003 |
| SERPINA3 |
Serpin peptidase inhibitor, clade A, member 3 |
0.43 |
0.20 |
2.16 |
0.017 |
| STC2 |
Stanniocalcin 2 |
0.79 |
0.38 |
2.05 |
0.019 |
|
Genes Associated with Breast Cancer Progression | |||||
| CLDN7 |
Claudin 7 |
1.76 |
0.66 |
2.67 |
0.006 |
| DLC1 | Deleted in liver cancer 1 | 4.27 | 0.94 | 4.52 | 0.023 |
a Average Gene Expression of Caucasion-American Women (CAW, n = 12).
b Average Gene Expression of African-Amercian Women (AAW, n = 12).
c Gene Expression Fold Change Relative to the Average Gene Expression of AAW.
d P-values calculated using the Wilcoxin Rank Sum Test.